Unknown

Dataset Information

0

The path of least resistance: aggressive or moderate treatment?

ABSTRACT: The evolution of resistance to antimicrobial chemotherapy is a major and growing cause of human mortality and morbidity. Comparatively little attention has been paid to how different patient treatment strategies shape the evolution of resistance. In particular, it is not clear whether treating individual patients aggressively with high drug dosages and long treatment durations, or moderately with low dosages and short durations can better prevent the evolution and spread of drug resistance. Here, we summarize the very limited available empirical evidence across different pathogens and provide a conceptual framework describing the information required to effectively manage drug pressure to minimize resistance evolution.

SUBMITTER: Kouyos RD 

PROVIDER: S-EPMC4211439 | biostudies-literature | 2014 Nov

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

The evolution of resistance to antimicrobial chemotherapy is a major and growing cause of human mortality and morbidity. Comparatively little attention has been paid to how different patient treatment strategies shape the evolution of resistance. In particular, it is not clear whether treating individual patients aggressively with high drug dosages and long treatment durations, or moderately with low dosages and short durations can better prevent the evolution and spread of drug resistance. Here  ...[more]

Similar Datasets

Unknown Drug-induced resistance evolution necessitates less aggressive treatment.
| S-EPMC8491903 | biostudies-literature
Unknown The Path of Least Resistance.
| S-EPMC8414532 | biostudies-literature
Unknown Aggressive or moderate drug therapy for infectious diseases? Trade-offs between different treatment goals at the individual and population levels.
| S-EPMC6742410 | biostudies-literature
Unknown Aggressive multiple sclerosis (2): Treatment.
| S-EPMC7412878 | biostudies-literature
Unknown Mitomycin C treatment induces resistance and enhanced migration via phosphorylated Akt in aggressive lung cancer cells.
| S-EPMC5346766 | biostudies-literature
Unknown Precision antimicrobial therapeutics: the path of least resistance?
| S-EPMC5829159 | biostudies-literature
Unknown Aggressive treatment style and surgical outcomes.
| S-EPMC3029844 | biostudies-literature
Unknown CHARTing a Path to Pragmatic Tobacco Treatment Research.
| S-EPMC5919279 | biostudies-literature
Unknown Treatment Approaches to Moderate to Severe Psoriasis.
| S-EPMC5713395 | biostudies-other
Unknown Pazopanib: a novel treatment option for aggressive fibromatosis.
| S-EPMC5131445 | biostudies-literature